STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

| Application Serial Number: | 10/553,906B |
|----------------------------|-------------|
| Source: | 1 FWO, |
| Date Processed by STIC: | 11/8/06 |
| • | |

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.4.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/10/06

Raw Sequence Listing Error Summary

| ERROR DETECTED | SUGGESTED CORRECTION SERIAL NUMBER: 10/553,906 B |
|---------------------------------------|--|
| ATTN: NEW RULES CASES: | PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE |
| 1Wrapped Nucleics Wrapped Aminos | The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping." |
| 2Invalid Line Length | The rules require that a line not exceed 72 characters in length. This includes white spaces. |
| Misaligned Amino Numbering Non-ASCII | The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead. |
| 4Non-ASCII | The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text. |
| 5Variable Length | Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing. |
| 6PatentIn 2.0 "bug" | A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences. |
| 7Skipped Sequences (OLD RULES) | Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences. |
| | Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000 |
| 9Use of n's or Xaa's (NEW RULES) | Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents. |
| 10Invalid <213> Response | Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence. (see item 11 below) |
| Use of <220> | Sequence(s)missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section or use "chemically synthesized" as explanation. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32), also Sec. 1.823 of Sequence Rules |
| "bug" | Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk. |
| 13 Misuse of n/Xaa | "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid |



IFWO

RAW SEQUENCE LISTING

DATE: 11/08/2006

PATENT APPLICATION:

US/10/553,906B

TIME: 13:15:36

Input Set : A:\PTO.RJ.txt

Output Set: N:\CRF4\11082006\J553906B.raw

3 <110 > APPLICANT: Skanemejerier AB

5 <120> TITLE OF INVENTION: NEW ENZYME AND ITS USE 7 <130> FILE REFERENCE: 75086

C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/553,906B

C--> 9 <141> CURRENT FILING DATE: 2005-10-21

9 <150> PRIOR APPLICATION NUMBER: US 60/320,139

10 <151> PRIOR FILING DATE: 2003-04-24

12 <150> PRIOR APPLICATION NUMBER: US 60/481,598

13 <151> PRIOR FILING DATE: 2003-11-05

15 <160> NUMBER OF SEQ ID NOS: 18

17 <170> SOFTWARE: PatentIn version 3.2

this is not the inventor title
this is not the inventor. Little
is USE

in official U.S.

19

8 see 40 (see p. 3)

8 see 4 on

Even funnous

Sheet

ERRORED SEQUENCES

E--> 708/1

690 <210> SEQ ID NO: 18

691 <211> LENGTH: 31

692 <212> TYPE: DNA

693 <213> ORGANISM: Unknown

695 <220> FEATURE:

Artificial 696 <223> OTHER INFORMATION:

698 <400> SEQUENCE: 18

699 acgtcgactt accagcacca taacagccaa g

insufficient response - qué source d) genetice same ena (see item/1 on in Jegs. 10-15,17

VERIFICATION SUMMARY

DATE: 11/08/2006

PATENT APPLICATION: US/10/553,906B

TIME: 13:15:37

Input Set : A:\PTO.RJ.txt

Output Set: N:\CRF4\11082006\J553906B.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application No

L:9 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:238 M:283 W: Missing Blank Line separator, <400> field identifier

L:401 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:900

L:708 M:254 E: No. of Bases conflict, this line has no nucleotides.

Attorney Docket No. 71752-81710 International Application No. PCT/SE2004/000628

AMENDMENTS TO THE SPECIFICATION:

On page 1, before line 1, please insert:

On page 1, after line 1, please insert:

-- Cross Reference to Related Applications

This application is a national stage application of International Application PCT/SE2004/000628, filed April 23, 2004, designating the United States of America, which claims the benefit of Provisional Patent Application No. 60/320,139, filed April 24, 2003 and Provisional Patent Application No. 60/481,598, filed November 5, 2003. Field of the Invention--

Please replace the existing abstract with the following, which also follows on a separate sheet at the conclusion of this submission:

-- An isolated human alkaline sphingomyelinase (Alk-Smase) or a variant thereof is capable of hydrolysing sphingomyelin. Methods are provided for isolating human Alk-Smase and for preparing human recombinant Alk-Smase. Further methods are provided for the use of the enzyme for the treatment of colon cancer.--

On page 1, before line 1, please unserv.

-- Title of the Invention-
On page 1, please amend line 1 as follows:

NEW ENZYME AND ITS USE Human Alkaline Sphingomyelinase and use thereof

Lo Ular